Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Tasly Pharmaceutical Group Co's PB Ratio or its related term are showing as below:
SHSE:600535'
s PB Ratio Range Over the Past 10 Years
Min: 1.17 Med: 1.92 Max: 6.18
Current: 1.86
During the past 13 years, Tasly Pharmaceutical Group Co's highest PB Ratio was 6.18. The lowest was 1.17. And the median was 1.92.
SHSE:600535's PB Ratio is ranked better than 50.27% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs SHSE:600535: 1.86
During the past 12 months, Tasly Pharmaceutical Group Co's average Book Value Per Share Growth Rate was 7.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 0.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Tasly Pharmaceutical Group Co was 81.20% per year. The lowest was -2.40% per year. And the median was 14.30% per year.
Back to Basics: PB Ratio
Tasly Pharmaceutical Group Co (SHSE:600535) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tasly Pharmaceutical Group Co PB Ratio Related Terms
Tasly Pharmaceutical Group Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tasly Pharmaceutical Group Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Tasly Pharmaceutical Group Co's PB Ratio falls into.
Tasly Pharmaceutical Group Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tasly Pharmaceutical Group Co (SHSE:600535) has a PB Ratio of 1.86 as of Jul. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tasly Pharmaceutical Group Co and its competitors. This is near median its historical median of 1.92. Over the past decade, Tasly Pharmaceutical Group Co's PB Ratio has ranged from 1.17 to 6.18. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #458 out of 921 companies in the Drug Manufacturers industry, placing it in the top 49.7%.
Is Tasly Pharmaceutical Group Co's PB Ratio too high?
Tasly Pharmaceutical Group Co's current PB Ratio of 1.86 is near median its 10-year median of 1.92. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 6.18. The Drug Manufacturers industry median PB Ratio is 1.88. Tasly Pharmaceutical Group Co's value of 1.86 is 1.1% below this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #458 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #458 out of 921 companies for PB Ratio. This puts Tasly Pharmaceutical Group Co in the upper half of its industry. The industry median PB Ratio is 1.88. Tasly Pharmaceutical Group Co's value of 1.86 is 1.1% below this benchmark. Historically, Tasly Pharmaceutical Group Co's own PB Ratio has ranged from 1.17 to 6.18 over the past decade. While the company's 10-year median is 1.92 vs. the industry median of 1.88, Tasly Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current PB Ratio of 1.86 is 1.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tasly Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current PB Ratio is 1.86, which is near median its own 10-year median of 1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.10, compared to a current price of ¥15.93 — trading 5.5% above its estimated fair value. The current PB Ratio is 1.86, which is near median its 10-year median of 1.92 and 1.1% below the Drug Manufacturers industry median of 1.88. Tasly Pharmaceutical Group Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current PB Ratio is 1.86 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥15.93 is trading 5.5% above its estimated GF Value™ of ¥15.10.
GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:600535:
PB Ratio: 1.86 (near median its 10-year median of 1.92)
GF Value™: ¥15.10 vs. price of ¥15.93 (5.5% above fair value)
Industry Position: 1.1% below the Drug Manufacturers median (#458 of 921)
No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tasly Pharmaceutical Group Co Business Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
78GF Score
Get the complete analysis for SHSE:600535
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600535 has been successfully added to your 
